Key facts: MRNA melanoma combo ~42% risk cut; EU, FDA ok; Citi Sell

Moderna's Phase 3 combo vaccine with Keytruda reduces melanoma recurrence and death risk by about 42%, gaining EU and FDA approval. Analysts debate the cost-effectiveness of manufacturing the personalized cancer vaccine despite positive clinical results.

This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 12 Oct 2026 and 24 Oct 2026.